Cargando…

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials

OBJECTIVE: We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programmed cell death 1 (PD-1) drugs, compared with control treatments, including chemotherapy, targeted drugs, or placebo. Further we compared the occurrence of immune -related events in patients trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yukun, Kong, Dejiu, Wang, Chaokun, Chen, Jing, Li, Jing, Liu, Zhiwei, Li, Xinyang, Wang, Ziming, Yao, Ge, Wang, Xinshuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588773/ https://www.ncbi.nlm.nih.gov/pubmed/33084525 http://dx.doi.org/10.1177/1533033820967454

Ejemplares similares

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis
por: Xu, Wentao, et al.
Publicado: (2023)

The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
por: Yang, Yan-Li, et al.
Publicado: (2019)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
por: Wang, Hao, et al.
Publicado: (2021)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2020)

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020)

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
por: Xu, Huilin, et al.
Publicado: (2020)

Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer
por: Chen, Jing, et al.
Publicado: (2021)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Endoscopic retrograde cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused on adverse events
por: Mashiana, Harmeet Singh, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis
por: Geng, Zhe, et al.
Publicado: (2018)

Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis
por: Nso, Nso, et al.
Publicado: (2020)

Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis
por: Guo, Wei, et al.
Publicado: (2017)

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
por: Jin, Liu, et al.
Publicado: (2020)

Association between low ambient temperature during pregnancy and adverse birth outcomes: A systematic review and meta-analysis
por: Ruan, Tiechao, et al.
Publicado: (2023)

The best surgical strategy for anal fistula based on a network meta-analysis
por: Wang, Qi, et al.
Publicado: (2017)

Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis
por: Zhang, Tao, et al.
Publicado: (2017)

Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review
por: Bai, Yang, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Association Between Psychosocial Disorders and Gastroesophageal Reflux Disease: A Systematic Review and Meta-analysis
por: He, Meijun, et al.
Publicado: (2022)

Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose–response meta analysis of prospective cohort studies
por: Shi, Jun, et al.
Publicado: (2017)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis
por: Pei, Wen-Guang, et al.
Publicado: (2023)

Timing of surgical operation for patients with intra-abdominal infection: A systematic review and meta-analysis
por: Song, Shu-Rui, et al.
Publicado: (2023)

Bioinformatics analysis on enrichment analysis of potential hub genes in breast cancer
por: Wei, Limin, et al.
Publicado: (2021)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Association Between Diabetes Mellitus and Outcomes of Patients with Sepsis: A Meta-Analysis
por: Wang, Zhiwei, et al.
Publicado: (2017)

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis
por: Cao, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fnbpv0dhho7tl89217279j3go6